Key result
Micra leadless pacemakers remain free of endocarditis despite a ~10% rate of bacteremia.
Why the study?
Transvenous permanent pacemaker related infection is a severe condition with significant morbidity and mortality, and leadless pacemakers may be more resistant to bacterial seeding during bloodstream infection due to their design.
Cohort (n=155)
No
In a retrospective cohort, patients with leadless pacemakers who developed systemic bacteraemia did not show evidence of device endocarditis, suggesting the device may be resistant to bacterial seeding.
Bacteraemia without endocarditis in this leadless pacemaker cohort; hypothesis-generating and leaves open comparative infection risk versus transvenous systems.
Background: Transvenous permanent pacemaker related infection is a severe condition associated with significant morbidity and mortality. Leadless pacemakers may be more resistant to bacterial seeding during bloodstream infection because of its small surface area and encapsulation in the right ventricle. This study reports the incidence and outcomes of bacteraemia in patients implanted with a Micra leadless pacemaker. We present 18F-FDG PET/CT findings obtained in a sub-group of patients. Methods: We report a retrospective cohort study of 155 patients who underwent a Micra TPS implant procedure at the University Hospitals of Leuven between July 2015 and July 2019. We identified the patients who developed an episode of bacteraemia, proved by ≥2 positive blood cultures. Results: Of the 155 patients, 15 patients presented an episode of bacteraemia at a median of 226 days (range: 3-1129) days after the implant procedure. Gram positive species accounted for 73.3% (n=11) of the bacteraemia including Staphylococcus (n=5), Enterococcus (n=3) and Streptococcus (n=3). The source of infection was identified in 9 patients (60%) including endocarditis in 4 patients, urinary tract in 3 patients, and skin in 2 patients. 18F-FDG PET/CT imaging performed in 6 patients did not show sign of infection around the leadless pacemaker. Bacteraemia was resolved in all patients after adequate antibiotherapy. Four patients died early during follow up. For all other patients, there were no recurrence of bacteraemia during a median follow up of 263 days (range 15-1134). Conclusion: In our small cohort, no leadless pacemaker endocarditis was observed among patients with bacteraemia.
No takes yet. Share an insight, caveat, or question.
Garweg et al. (2020) conducted a cohort in Bacteraemia after leadless pacemaker implantation (n=155). Micra leadless pacemaker implantation was evaluated on Incidence of bacteraemia. Among 155 patients with a Micra leadless pacemaker, 15 (9.7%) developed bacteraemia, but none developed leadless pacemaker endocarditis.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: